Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker;Efectos secundarios asociados al tratamiento con maraviroc y otros antagonistas de CCR5. Impacto potencial del bloqueo del receptor CCR5

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 11, 2008, Pages 23-27

  Arribas López, José R ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Adverse effects; CCR5; HIV; Maraviroc

Indexed keywords

ANTIRETROVIRUS AGENT; APLAVIROC; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHOLESTEROL; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN; LAMIVUDINE PLUS ZIDOVUDINE; LOW DENSITY LIPOPROTEIN; MARAVIROC; PLACEBO; TRIACYLGLYCEROL; 873140 COMPOUND; BENZOIC ACID DERIVATIVE; CHEMOKINE RECEPTOR CCR5; CYCLOHEXANE DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PIPERAZINE DERIVATIVE; SPIRO COMPOUND; TRIAZOLE DERIVATIVE; VIRUS ENVELOPE PROTEIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENCEPHALITIS; FOLLOW UP; HOMOZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INCIDENCE; LIPOPROTEIN BLOOD LEVEL; LIVER TOXICITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MUTATION; NEOPLASM; NONHUMAN; PHASE 3 CLINICAL TRIAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS INFECTION; WEST NILE FLAVIVIRUS; ADULT; COMORBIDITY; DISEASE PREDISPOSITION; DRUG ANTAGONISM; DRUG DESIGN; GENE DELETION; GENETICS; HYPERLIPIDEMIA; INFECTION; MEMBRANE FUSION; PHYSIOLOGY; REVIEW; STATISTICS; TOXIC HEPATITIS; VIRUS ATTACHMENT; VIRUS ENTRY;

ADULT; BENZOATES; CLINICAL TRIALS AS TOPIC; COMORBIDITY; CYCLOHEXANES; DISEASE SUSCEPTIBILITY; DRUG DESIGN; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HEPATITIS, TOXIC; HIV FUSION INHIBITORS; HIV INFECTIONS; HOMOZYGOTE; HUMANS; HYPERLIPIDEMIAS; INCIDENCE; INFECTION; MEMBRANE FUSION; NEOPLASMS; PIPERAZINES; RECEPTORS, CCR5; SEQUENCE DELETION; SPIRO COMPOUNDS; TRIAZOLES; VIRUS ATTACHMENT; VIRUS INTERNALIZATION;

EID: 65449158357     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(08)76560-1     Document Type: Article

References (12)

1. Celsentri®. Ficha técnica.
2. J. Lalezari, J. Goodrich, E. DeJesus, et al. Efficacy and safety of maraviroc in antiretroviral-experienced patients infected with CCR5-tropic HIV-1: 48-week results of MOTIVATE 1 [abstract H-718a] 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago 2007
3. G. Fätkenheuer, I. Konourina, M. Nelson, et al. Efficacy and safety of maraviroc (MVC) plus optimized background therapy (OBT) in varaemic, antiretroviral treatment-experienced patients infected with CCR5-tropic (R5) HIV-1 in Europe, Australia and North America (MOTIVATE 2): 48-week results 11th European AIDS Conference/EACS Madrid 2007 [abstract PS3/5]
4. D. Hardy, J. Reynes, I. Konourina, et al. Efficacy and safety of maraviroc plus optimized background therapy in treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week combined analysis of the MOTIVATE studies 15th Conference on Retroviruses and Opportunistic Infections (CROI) Boston, February 3-6 2008 [abstract 792]
5. W.G. Nichols, H.M. Steel, T. Bonny, K. Adkison, L. Curtis, and J. Millard Hepatotoxicity observed in clinical trials of aplaviroc (GW873140) Antimicrob Agents Chemother 52 2008 858 865 (Pubitemid 351358363)
6. I.M. Hoepelman, A. Ayoub, J. Heera, et al. The incidence of severe liver enzyme abnormalities and hepatic adverse events in the Maraviroc Clinical Development Programme 11th European AIDS Conference (EACS) Madrid, Spain. October 24-27 2007
7. R.M. Gulick, Z. Su, C. Flexner, M.D. Hughes, P.R. Skolnik, T.J. Wilkin AIDS Clinical Trials Group 5211 Team Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211 J Infect Dis 196 2007 304 312 (Pubitemid 47047471)
8. Saag M, Ive P, Heera J, Tawadrous M, DeJesus E, Clumeck N, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV-1: week 48 results of the MERIT study. Fourth International AIDS Society Conference on HIV Treatment and Pathogenesis, Sydney [abstract WESS104, 2007].
9. R. Liu, W.A. Paxton, S. Choe, D. Ceradini, S.R. Martin, and R. Horuk Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection Cell 86 1996 367 377 (Pubitemid 26272077)
10. J. Wheeler, M. McHale, V. Jackson, and M. Penny Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: experience in a drug development programme for maraviroc Antivir Ther 12 2007 233 245 (Pubitemid 46569908)
11. J.K. Lim, C.Y. Louie, C. Glaser, C. Jean, B. Johnson, and H. Johnson Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic J Infect Dis 197 2008 262 265 (Pubitemid 351263445)
12. E. Kindberg, A. Mickien, and C. Ax A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis J Infect Dis 197 2008 266 269 (Pubitemid 351263446)